GLG News by Pancreatic Cancer Oncologists in the U.S.

Revlimid benefits are often over-stated in non-5Q minus MDS. The cost is a hurdle for many patients with poor prescription plans. Vidaza and Dacogen seem superior in my experience for higher risk patients.

The recent study implies and improved outcome with zevalin The radio immunoconjugates have bee anything but a success story

Xeloda has proven equal to infusional 5FU in recent colorectal cancer trial Xeloda is an oral agent versus iv 5FU and is therefore prefered therapy Xeloda has a diffrenet toxicity profile than infusional 5FU

CMS is doing right thing. This will aviod pt fall and bedsore during hospitalzation

Recent studies demonstrate benefit with picoplatin in HRPCa Other trials have used differnt platinums such as Satraplatin in HRPCa with encouraging results Othe tumors have also benefitted from the newer second/ third generation platinums

CMS recently tried to glut tohe use of ESAs ESAs have had considerable backing in trial results EsAs situation is just a continuation of the reimbursement disaster being established by CMS with indemity plans to follow

Ixabepilone is the first in a new class of antineoplastic agents.   This international, randomized, phase II trial assessed two administration schedules of ixabepilone as second-line therapy in patients with non–small-cell lung cancer There may be concern for cytotoxics versus biologics in todays...

Erbitux has promising results in colorectal cancer trials. Erbitux has a  future in colorectal cancer. Erbitux has some pending trilas that could explode the drug's popularity. Erbitux may have an advantage over Avastin .

Vegf trap useful in wet MD Vegf trap will be a proft maker for this indication Vegf trap is also a contender in cancer therapy

Statins have recent reputation as cancer promoting. Statins also have demonstrated benefit in treating cancer patients Statins can be eliminated based on the first issue